Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Debio 1347 + Fulvestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Debio 1347 | CH5183284|FF284|debiopharm 1347 | FGFR1 Inhibitor 27 FGFR2 Inhibitor 22 FGFR3 Inhibitor 19 | Debio 1347 inhibits FGFR-1, -2, and -3, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and angiogenesis, and increased cell death in FGFR-overexpressing tumor cells (PMID: 30745300). | |
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 25 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03344536 | Phase Ib/II | Debio 1347 + Fulvestrant | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | Completed | USA | 0 |